Presynaptic regulation of extracellular dopamine levels in the medial prefrontal cortex and striatum during tyrosine depletion

Psychopharmacology

Volumn 227, Issue 2, 2013, Pages 363-371

  Brodnik, Zachary ^a   Double, Manda ^a   Jaskiw, George E ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

DOPA; Dopamine; Prefrontal cortex; Receptor; Striatum; Tyrosine

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; PHENYLALANINE; QUINPIROLE; TYROSINE;

AMINO ACID BRAIN LEVEL; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE LEVEL; DIALYSIS; ELECTROCHEMICAL DETECTION; EXTRACELLULAR MATRIX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEDIAL PREFRONTAL CORTEX; NONHUMAN; PREFRONTAL CORTEX; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; REVERSE DIALYSIS;

AMINO ACIDS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MICRODIALYSIS; PREFRONTAL CORTEX; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; TYROSINE;

EID: 84879603697     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-2977-0     Document Type: Article

References (90)

1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97:8104-8109
2. Adachi Y, Uchihashi Y, Watanabe K, Satoh T (2000) Halothane anesthesia decreases the extracellular level of dopamine in rat striatum: a microdialysis study in vivo. J Anesth 14:82-90
3. Angrist B, Rotrosen J, Gershon S (1980) Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology (Berlin) 67:31-38
4. Anzalone A, Lizardi-Ortiz JE, Ramos M, De MC, Hopf FW, Iaccarino C, Halbout B, Jacobsen J, Kinoshita C, Welter M, Caron MG, Bonci A, Sulzer D, Borrelli E (2012) Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci 32:9023-9034
5. Argiolas A, Fadda F, Melis MR, Serra G, Gessa GL (1979) Chronic haloperidol causes persistent increase in 3,4-dihydroxyphenylacetic acid (DOPAC) concentration in the substantia nigra but not in the ventral tegmental area. Brain Res 175:178-182
6. Bannon MJ, Bunney EB, Roth RH (1981a) Mesocortical dopamine neurons: rapid transmitter turnover compared to other brain catecholamine systems. Brain Res 218:376-382
7. Bannon MJ, Michaud RL, Roth RH (1981b) Mesocortical dopamine neurons: lack of autoreceptors modulating dopamine synthesis. Mol Pharmacol 19:270-275
8. Bannon MJ, Reinhard JF Jr, Bunney EB, Roth RH (1982) Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurones. Nature 296:444-446
9. Bardo MT, Bowling SL, Pierce RC (1990) Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli. Psychopharmacology (Berlin) 101:338-343
10. Bean AJ, During MJ, Roth RH (1990) Effects of dopamine autoreceptor stimulation on the release of colocalized transmitters: in vivo release of dopamine and neurotensin from rat prefrontal cortex. Neurosci Lett 108:143-148
11. Best JA, Nijhout HF, Reed MC (2009) Homeostatic mechanisms in dopamine synthesis and release: a mathematical model. Theor Biol Med Model 6:21
12. Biggio G, Porceddu ML, Gessa GL (1976) Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3′,5′-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine. J Neurochem 26:1253-1255
13. Bongiovanni R, Kyser AN, Jaskiw GE (2012) Tyrosine depletion lowers in vivo DOPA synthesis in ventral hippocampus. Eur J Pharmacol 696:70-76
14. Bongiovanni R, Newbould E, Jaskiw GE (2008) Tyrosine depletion lowers dopamine synthesis and desipramine-induced prefrontal cortex catecholamine levels. Brain Res 1190:39-48
15. Bradberry CW, Karasic DH, Deutch AY, Roth RH (1989) Regionally-specific alterations in mesotelencephalic dopamine synthesis in diabetic rats: association with precursor tyrosine. J Neural Transm 78:221-229
16. Budygin EA, Gainetdinov RR, Kilpatrick MR, Rayevsky KS, Mannisto PT, Wightman RM (1999) Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur J Pharmacol 370:125-131
17. Cartier EA, Parra LA, Baust TB, Quiroz M, Salazar G, Faundez V, Egana L, Torres GE (2010) A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J Biol Chem 285:1957-1966
18. Cass WA, Gerhardt GA (1995) In vivo assessment of dopamine uptake in rat medial prefrontal cortex: comparison with dorsal striatum and nucleus accumbens. J Neurochem 65:201-207
19. Chiodo LA, Bannon MJ, Grace AA, Roth RH, Bunney BS (1984) Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience 12:1-16
20. Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI (1995) The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 15:1714-1723
21. de La Fuente-Fernandez, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, Stoessl AJ (2001) Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 21:1151-1159
22. de Lange EC, de Boer AG, Breimer DD (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125-148
23. +. Biochem Pharmacol 31:3289-3296
24. Devoto P, Flore G, Pani L, Gessa GL (2001) Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 6:657-664
25. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, Sokoloff P (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20:8677-8684
26. Ellis KA, Mehta MA, Naga Venkatesha Murthy PJ, McTavish SF, Nathan PJ, Grasby PM (2007) Tyrosine depletion alters cortical and limbic blood flow but does not modulate spatial working memory performance or task-related blood flow in humans. Hum Brain Mapp 28:1136-1149
27. Engelman K, Horwitz D, Jequier E, Sjoerdsma A (1968) Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 47:577-594
28. Fadda F, Gessa GL, Marcou M, Mosca E, Rossetti Z (1984) Evidence for dopamine autoreceptors in mesocortical dopamine neurons. Brain Res 293:67-72
29. Favard C, Simon A, Vigny A, Nguyen-Legros J (1990) Ultrastructural evidence for a close relationship between dopamine cell processes and blood capillary walls in Macaca monkey and rat retina. Brain Res 523:127-133
30. Fernstrom MH, Fernstrom JD (1995) Acute tyrosine depletion reduces tyrosine hydroxylation rate in rat central nervous system. Life Sci 57:97-102
31. Flietstra RJ, Levant B (1998) Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life Sci 62:1825-1831
32. Freeman KA, Tallarida RJ (1994) A quantitative study of dopamine control in the rat striatum. J Pharmacol Exp Ther 268:629-638
33. Galloway MP, Wolf ME, Roth RH (1986) Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J Pharmacol Exp Ther 236:689-698
34. Garris PA, Wightman RM (1994) Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 14:442-450
35. 3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol 211:189-194
36. Gijsman HJ, Scarna A, Harmer CJ, McTavish SB, Odontiadis J, Cowen PJ, Goodwin GM (2002) A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacology (Berlin) 160:192-197
37. Harmer CJ, McTavish SF, Clark L, Goodwin GM, Cowen PJ (2001) Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacology (Berlin) 154:105-111
38. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ (2004) Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. J Psychopharmacol 18:32-40
39. Ikeda M, Fahien LA, Udenfriend S (1966) A kinetic study of bovine adrenal tyrosine hydroxylase. J Biol Chem 241:4452-4456
40. Imperato A, Di Chiara G (1988) Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur J Pharmacol 156:385-393
41. Iuvone PM, Dunn AJ (1986) Tyrosine hydroxylase activation in mesocortical 3,4-dihydroxyphenylethylamine neurons following footshock. J Neurochem 47:837-844
42. Jaskiw GE, Bongiovanni R (2004) Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat. Psychopharmacology (Berlin) 172:100-107
43. Jaskiw GE, Karoum F, Freed WJ, Phillips I, Kleinman JE, Weinberger DR (1990) Effect of ibotenic acid lesions of the medial prefrontal cortex on amphetamine-induced locomotion and regional brain catecholamine concentrations in the rat. Brain Res 534:263-272
44. Jaskiw GE, Kirkbride B, Bongiovanni R (2006) In rats chronically treated with clozapine, tyrosine depletion attenuates the clozapine-induced in vivo increase in prefrontal cortex dopamine and norepinephrine levels. Psychopharmacology (Berlin) 185:416-422
45. Jaskiw GE, Kirkbride B, Newbould E, Young D, Durkalski V, Bongiovanni R (2005) Clozapine-induced dopamine release in the medial prefrontal cortex is augmented by a moderate concentration of locally administered tyrosine but attenuated by high tyrosine concentrations or by tyrosine depletion. Psychopharmacology (Berlin) 179:713-724
46. Jaskiw GE, Newbould E, Bongiovanni R (2008a) Gamma-butyrolactone-induced dopamine accumulation in prefrontal cortex is affected by tyrosine availability. Eur J Pharmacol 589:106-109
47. Jaskiw GE, Newbould E, Bongiovanni R (2008b) Tyrosine availability modulates potassium-induced striatal catecholamine efflux in vivo. Brain Res 1209:74-84
48. Kaenmaki M, Tammimaki A, Myohanen T, Pakarinen K, Amberg C, Karayiorgou M, Gogos JA, Mannisto PT (2010) Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 114:1745-1755
49. Kapatos G, Zigmond M (1977) Dopamine biosynthesis from l-tyrosine and l-phenylalanine in rat brain synaptosomes: preferential use of newly accumulated precursors. J Neurochem 28:1109-1119
50. Kaufman S, Kaufman EE (1985) Tyrosine Hydroxylase. In: Blakley RL, Benkovic SJ (eds) Chemistry and biochemistry of the pterins. Wiley, New York, pp 251-352
51. Kilts CD, Anderson CM, Ely TD, Nishita JK (1987) Absence of synthesis-modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations. J Neurosci 7:3961-3975
52. Kuczenski RT, Mandell AJ (1972) Regulatory properties of soluble and particulate rat brain tyrosine hydroxylase. J Biol Chem 247:3114-3122
53. 1H-3-benzazepine on the release of striatal dopamine investigated by means of brain dialysis. Neurosci Lett 117:264-268
54. Levant B, Grigoriadis DE, De Souza EB (1995) Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. Eur J Pharmacol 278:243-247
55. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A 89:8155-8159
56. LeWitt PA, Ondo WG, Van LB, Bottini PB (2009) Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease. Clin Neuropharmacol 32:89-93
57. Lythe KE, Anderson IM, Deakin JF, Elliott R, Strickland PL (2005) Lack of behavioural effects after acute tyrosine depletion in healthy volunteers. J Psychopharmacol 19:5-11
58. Mao A, Freeman KA, Tallarida RJ (1996) Transient loss of dopamine autoreceptor control in the presence of highly potent dopamine agonists. Life Sci 59:L317-L324
59. Masana M, Bortolozzi A, Artigas F (2011) Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neuropsychopharmacol 14:53-68
60. McTavish SF, Cowen PJ, Sharp T (1999a) Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology (Berlin) 141:182-188
61. McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM, Cowen PJ (2001) Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 179:356-360
62. McTavish SF, McPherson MH, Sharp T, Cowen PJ (1999b) Attenuation of some subjective effects of amphetamine following tyrosine depletion. J Psychopharmacol 13:144-147
63. Mehta MA, Gumaste D, Montgomery AJ, McTavish SF, Grasby PM (2005) The effects of acute tyrosine and phenylalanine depletion on spatial working memory and planning in healthy volunteers are predicted by changes in striatal dopamine levels. Psychopharmacology (Berlin) 180:654-663
64. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M (1987) Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31:592-598
65. Menniti FS, Diliberto EJ Jr (1989) Newly synthesized dopamine as the precursor for norepinephrine synthesis in bovine adrenomedullary chromaffin cells. J Neurochem 53:890-897
66. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS (1996) Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53:117-128
67. 11C]raclopride PET study. Am J Psychiatry 160:1887-1889
68. Neff NH, Wemlinger TA, Duchemin AM, Hadjiconstantinou M (2006) Clozapine modulates aromatic l-amino acid decarboxylase activity in mouse striatum. J Pharmacol Exp Ther 317:480-487
69. Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97-103
70. Palmour RM, Ervin FR, Baker GB, Young SN (1998) An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacology (Berlin) 136:1-7
71. Pothos E, Desmond M, Sulzer D (1996) L-3,4-dihydroxyphenylalanine increases the quantal size of exocytotic dopamine release in vitro. J Neurochem 66:629-636
72. Rodenhuis N, Dijkstra D, de BP, Vermeulen ES, Timmerman W, Wikstrom HV (2000) Dopamine D(2) activity of R-(-)-apomorphine and selected analogs: a microdialysis study. Eur J Pharmacol 387:39-45
73. Roth RH (1984) CNS dopamine autoreceptors: distribution, pharmacology, and function. Ann N Y Acad Sci 430:27-53
74. Santiago M, Machado A, Cano J (1993a) Effects of age and dopamine agonists and antagonists on striatal dopamine release in the rat: an in vivo microdialysis study. Mech Ageing Dev 67:261-267
75. Santiago M, Machado A, Cano J (1993b) Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur J Pharmacol 239:83-91
76. Sarre S, Ebinger G, Michotte Y (1996) Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists. Eur J Pharmacol 296:247-260
77. Stanwood GD, Artymyshyn RP, Kung MP, Kung HF, Lucki I, McGonigle P (2000) Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295:1223-1231
78. Starke K, Gothert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864-989
79. Tam SY, Elsworth JD, Bradberry CW, Roth RH (1990) Mesocortical dopamine neurons: high basal firing rate frequency predicts tyrosine dependence of dopamine synthesis. J Neural Transm 81:97-110
80. Tanaka T, Vincent SR, Nomikos GG, Fibiger HC (1992) Effect of quinine on autoreceptor-regulated dopamine release in the rat striatum. J Neurochem 59:1640-1645
81. Tyler CB, Galloway MP (1992) Acute administration of amphetamine: differential regulation of dopamine synthesis in dopamine projection fields. J Pharmacol Exp Ther 261:567-573
82. Wang J, Lou H, Pedersen CJ, Smith AD, Perez RG (2009) 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 284:14011-14019
83. Waymire JC, Haycock JW (2002) Lack of regulation of aromatic l-amino acid decarboxylase in intact bovine chromaffin cells. J Neurochem 81:589-593
84. Westerink BH, De Vries JB (2001) A method to evaluate the diffusion rate of drugs from a microdialysis probe through brain tissue. J Neurosci Methods 109:53-58
85. Westerink BH, Kawahara Y, De Boer P, Geels C, De Vries JB, Wikstrom HV, Van Kalkeren A, Van Vliet B, Kruse CG, Long SK (2001) Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 412:127-138
86. Wolf ME, Roth RH (1990) Autoreceptor regulation of dopamine synthesis. Ann N Y Acad Sci 604:323-343, 323-343
87. Wu Q, Reith ME, Walker QD, Kuhn CM, Carroll FI, Garris PA (2002) Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. J Neurosci 22:6272-6281
88. Wurtman RJ, Larin F, Mostafapour S, Fernstrom JD (1974) Brain catechol synthesis: control by brain tyrosine concentration. Science 185:183-184
89. You ZB, Herrera-Marschitz M, Nylander I, Goiny M, O'Connor WT, Ungerstedt U, Terenius L (1994) The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis - II. Effects of dopamine D1 and D2 receptor agonists. Neuroscience 63:427-434
90. Zhang H, Sulzer D (2012) Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors. Basal Ganglia 2:5-13